Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference.
The company's President and CEO George Lasezkay, PharmD, JD, along with Chief Medical Officer and EVP, Head of Research and Development Victor Chong, MD, MBA, will engage in a Fireside Chat scheduled for Tuesday, February 11, 2025, at 9:20 a.m. ET.
Interested parties can access both the live and archived webcast through the Investors section of Clearside's website under Events and Presentations. The webcast recording will remain available for three months following the event.
Clearside Biomedical (Nasdaq: CLSD), una azienda biopharmaceutica specializzata nella somministrazione di terapie nella parte posteriore dell'occhio attraverso lo spazio suprachoroidale (SCS®), ha annunciato la sua partecipazione alla 35esima Conferenza Virtuale Annuale Oppenheimer sulle Scienze della Vita e della Salute.
Il presidente e CEO dell'azienda, George Lasezkay, PharmD, JD, insieme al Chief Medical Officer e EVP, Capo della Ricerca e Sviluppo, Victor Chong, MD, MBA, parteciperanno a un Fireside Chat programmato per martedì 11 febbraio 2025, alle 9:20 AM ET.
Le parti interessate possono accedere sia alla trasmissione in diretta che a quella registrata attraverso la sezione Investitori del sito web di Clearside, nella sezione Eventi e Presentazioni. La registrazione della trasmissione rimarrà disponibile per tre mesi dopo l'evento.
Clearside Biomedical (Nasdaq: CLSD), una compañía biofarmacéutica especializada en ofrecer terapias para la parte posterior del ojo a través del espacio suprachoroidal (SCS®), ha anunciado su participación en la 35ª Conferencia Virtual Anual Oppenheimer sobre Ciencias de la Salud.
El presidente y CEO de la empresa, George Lasezkay, PharmD, JD, junto con el Director Médico y EVP, Jefe de Investigación y Desarrollo, Victor Chong, MD, MBA, participarán en una Charla junto al Fuego programada para el martes 11 de febrero de 2025, a las 9:20 AM ET.
Las partes interesadas pueden acceder tanto a la transmisión en vivo como a la grabación a través de la sección de Inversores en el sitio web de Clearside, en la sección de Eventos y Presentaciones. La grabación del webcast estará disponible durante tres meses después del evento.
Clearside Biomedical (Nasdaq: CLSD)는 눈 뒤쪽에 치료제를 전달하는 데 특화된 생명공학 회사로, 초코리달 공간(SCS®)을 통해 치료제를 제공합니다. 이 회사는 오펜하이머 제35회 연례 의료 생명 과학 가상 회의에 참여할 것이라고 발표했습니다.
회사의 사장이자 CEO인 조지 라세즈카이, PharmD, JD와 최고 의료 책임자 및 EVP이자 연구 및 개발 책임자인 빅터 총, MD, MBA는 2025년 2월 11일 화요일 오전 9시 20분(ET)에 예정된 파이어사이드 채팅에 참여할 것입니다.
관심 있는 분들은 Clearside 웹사이트의 투자자 섹션에서 이벤트 및 프레젠테이션 아래에서 생중계 및 보관된 웹캐스트에 액세스할 수 있습니다. 웹캐스트 녹화는 이벤트 후 3개월 동안 제공됩니다.
Clearside Biomedical (Nasdaq: CLSD), une entreprise biopharmaceutique spécialisée dans l'administration de thérapies à l'arrière de l'œil via l'espace suprachoroïdal (SCS®), a annoncé sa participation à la 35ème Conférence Virtuelle Annuelle Oppenheimer sur les Sciences de la Vie et la Santé.
Le président et CEO de l'entreprise, George Lasezkay, PharmD, JD, ainsi que le Directeur Médical et EVP, Responsable de la Recherche et du Développement, Victor Chong, MD, MBA, participeront à une Discussion au Coin du Feu prévue pour le mardi 11 février 2025, à 9h20 ET.
Les parties intéressées peuvent accéder à la diffusion en direct ainsi qu'à l'enregistrement via la section des Investisseurs du site web de Clearside, sous Événements et Présentations. L'enregistrement du webinaire restera accessible pendant trois mois après l'événement.
Clearside Biomedical (Nasdaq: CLSD), ein biopharmazeutisches Unternehmen, das auf die Bereitstellung von Therapien für den hinteren Teil des Auges durch den suprachoroidalen Raum (SCS®) spezialisiert ist, hat seine Teilnahme an der 35. jährlichen virtuellen Gesundheits- und Life-Sciences-Konferenz von Oppenheimer angekündigt.
Der Präsident und CEO des Unternehmens, George Lasezkay, PharmD, JD, zusammen mit dem Chief Medical Officer und EVP, Leiter von Forschung und Entwicklung, Victor Chong, MD, MBA, wird an einem Fireside Chat teilnehmen, der für Dienstag, den 11. Februar 2025, um 9:20 Uhr ET geplant ist.
Interessierte Parteien können sowohl auf den Live-Streaming- als auch auf die aufgezeichnete Webcast-Übertragung über den Bereich Investoren auf der Website von Clearside unter Veranstaltungen und Präsentationen zugreifen. Die Aufzeichnung des Webcasts bleibt drei Monate nach der Veranstaltung verfügbar.
- None.
- None.
ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development, will participate in a Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference on Tuesday, February 11, 2025, at 9:20 a.m. ET.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical (CLSD) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access CLSD's Oppenheimer Conference presentation?
How long will CLSD's Oppenheimer Conference webcast be available?
Who will represent CLSD at the Oppenheimer Healthcare Conference 2025?
What is Clearside Biomedical's (CLSD) main technological focus?
